Skip to main content
Signal8

enVVeno Medical Corp (NVNO)

enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Devices

enVVeno Medical Corporation logo

enVVeno Medical Corporation

NASDAQ:NVNOHealthcare
-2.94%$5.77
CLOSED
AH$5.77+0.00%vs close
Mkt Cap$4.01M
EV-
Float691K
O/S695K
VOL11K sh
$ Vol$65K
RVOL0.34×
Inst Own12.6%
SI3.5%
Net Cash/Sh-
Dilution
enVVeno Medical Corporation logoNASDAQ:NVNOClosed$5.77-2.94%
Short interest (FINRA)
3.5%
Oct 30 (19d)

Float 690.75K · Signal8 dilution snapshot · Oct 29, 2026

24.1K
Oct 30 (19d)prev 11.8K▲ 104.8%
1.00
Oct 30 (19d)prev 1.00– 0.0%
Borrow (IBKR)

The cost to borrow NVNO shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.

IBKR borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
11.1%
Nov 17 (1d)prev 19.2%▼ 8.1 pts

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

206
Oct 30 (19d)prev 46▲ 347.8%
Price, short interest & fails to deliver
Short interest · today's share basis23 settlements
Fails to deliver5 settlement dates
Latest short interest settlements (today's share basis)
DateShares short
Oct 30, 202624.1K sh
Oct 15, 202611.8K sh
Sep 30, 202613.5K sh
Sep 15, 20269.4K sh
Aug 31, 20268.4K sh
Latest fails to deliver
DateShares failed
Oct 30, 2026206 sh
Sep 3, 202646 sh
Jul 1, 20262 sh
Apr 23, 202623 sh
Apr 17, 20262 sh

A stock split executed inside this window; every settlement plotted has been carried onto today’s share basis, so the line does not step at the split.

The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.

Off-exchange short volume
Nov 17
Latest sessions
DateReported short
Nov 17, 202611.1%
Nov 16, 202619.2%
Nov 13, 202644.8%
Nov 12, 202670.8%
Nov 11, 202631.7%
91-session median 47.5%mean 46.2%range 10.3–92.4%

130 calendar days requested; 92 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.

Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for NVNO: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually

As of the Oct 30, 2026 FINRA settlement, 24,103 NVNO shares were sold short (3.49% of a 691K-share float, 1.00 days to cover).